The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Premenstrual Dysphoric Disorder (PMDD) Market Research Report 2025
Synopsis
Premenstrual dysphoric disorder (PMDD) is a health problem that is similar to premenstrual syndrome (PMS) but is more serious. PMDD causes severe irritability, depression, or anxiety in the week or two before your period starts. Symptoms usually go away two to three days after your period starts.
The global Premenstrual Dysphoric Disorder (PMDD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Premenstrual Dysphoric Disorder (PMDD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Premenstrual Dysphoric Disorder (PMDD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Premenstrual Dysphoric Disorder (PMDD) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Premenstrual Dysphoric Disorder (PMDD) include Teva, Eli Liliy, Pfizer, Bayer, GSK, Apotex, Bristol Laboratories, Mylan and Allergan, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Premenstrual Dysphoric Disorder (PMDD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Premenstrual Dysphoric Disorder (PMDD).
Report Scope
The Premenstrual Dysphoric Disorder (PMDD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Premenstrual Dysphoric Disorder (PMDD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Premenstrual Dysphoric Disorder (PMDD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Teva
Eli Liliy
Pfizer
Bayer
GSK
Apotex
Bristol Laboratories
Mylan
Allergan
Segment by Type
Table Product
Inject Product
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Premenstrual Dysphoric Disorder (PMDD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Premenstrual dysphoric disorder (PMDD) is a health problem that is similar to premenstrual syndrome (PMS) but is more serious. PMDD causes severe irritability, depression, or anxiety in the week or two before your period starts. Symptoms usually go away two to three days after your period starts.
The global Premenstrual Dysphoric Disorder (PMDD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Premenstrual Dysphoric Disorder (PMDD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Premenstrual Dysphoric Disorder (PMDD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Premenstrual Dysphoric Disorder (PMDD) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Premenstrual Dysphoric Disorder (PMDD) include Teva, Eli Liliy, Pfizer, Bayer, GSK, Apotex, Bristol Laboratories, Mylan and Allergan, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Premenstrual Dysphoric Disorder (PMDD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Premenstrual Dysphoric Disorder (PMDD).
Report Scope
The Premenstrual Dysphoric Disorder (PMDD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Premenstrual Dysphoric Disorder (PMDD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Premenstrual Dysphoric Disorder (PMDD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Teva
Eli Liliy
Pfizer
Bayer
GSK
Apotex
Bristol Laboratories
Mylan
Allergan
Segment by Type
Table Product
Inject Product
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Premenstrual Dysphoric Disorder (PMDD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Premenstrual Dysphoric Disorder (PMDD) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Table Product
1.2.3 Inject Product
1.2.4 Others
1.3 Market by Application
1.3.1 Global Premenstrual Dysphoric Disorder (PMDD) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Premenstrual Dysphoric Disorder (PMDD) Market Perspective (2019-2030)
2.2 Premenstrual Dysphoric Disorder (PMDD) Growth Trends by Region
2.2.1 Global Premenstrual Dysphoric Disorder (PMDD) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Premenstrual Dysphoric Disorder (PMDD) Historic Market Size by Region (2019-2024)
2.2.3 Premenstrual Dysphoric Disorder (PMDD) Forecasted Market Size by Region (2025-2030)
2.3 Premenstrual Dysphoric Disorder (PMDD) Market Dynamics
2.3.1 Premenstrual Dysphoric Disorder (PMDD) Industry Trends
2.3.2 Premenstrual Dysphoric Disorder (PMDD) Market Drivers
2.3.3 Premenstrual Dysphoric Disorder (PMDD) Market Challenges
2.3.4 Premenstrual Dysphoric Disorder (PMDD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Premenstrual Dysphoric Disorder (PMDD) Players by Revenue
3.1.1 Global Top Premenstrual Dysphoric Disorder (PMDD) Players by Revenue (2019-2024)
3.1.2 Global Premenstrual Dysphoric Disorder (PMDD) Revenue Market Share by Players (2019-2024)
3.2 Global Premenstrual Dysphoric Disorder (PMDD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Premenstrual Dysphoric Disorder (PMDD) Revenue
3.4 Global Premenstrual Dysphoric Disorder (PMDD) Market Concentration Ratio
3.4.1 Global Premenstrual Dysphoric Disorder (PMDD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Premenstrual Dysphoric Disorder (PMDD) Revenue in 2023
3.5 Premenstrual Dysphoric Disorder (PMDD) Key Players Head office and Area Served
3.6 Key Players Premenstrual Dysphoric Disorder (PMDD) Product Solution and Service
3.7 Date of Enter into Premenstrual Dysphoric Disorder (PMDD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Premenstrual Dysphoric Disorder (PMDD) Breakdown Data by Type
4.1 Global Premenstrual Dysphoric Disorder (PMDD) Historic Market Size by Type (2019-2024)
4.2 Global Premenstrual Dysphoric Disorder (PMDD) Forecasted Market Size by Type (2025-2030)
5 Premenstrual Dysphoric Disorder (PMDD) Breakdown Data by Application
5.1 Global Premenstrual Dysphoric Disorder (PMDD) Historic Market Size by Application (2019-2024)
5.2 Global Premenstrual Dysphoric Disorder (PMDD) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Premenstrual Dysphoric Disorder (PMDD) Market Size (2019-2030)
6.2 North America Premenstrual Dysphoric Disorder (PMDD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Premenstrual Dysphoric Disorder (PMDD) Market Size by Country (2019-2024)
6.4 North America Premenstrual Dysphoric Disorder (PMDD) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Premenstrual Dysphoric Disorder (PMDD) Market Size (2019-2030)
7.2 Europe Premenstrual Dysphoric Disorder (PMDD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Premenstrual Dysphoric Disorder (PMDD) Market Size by Country (2019-2024)
7.4 Europe Premenstrual Dysphoric Disorder (PMDD) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Premenstrual Dysphoric Disorder (PMDD) Market Size (2019-2030)
8.2 Asia-Pacific Premenstrual Dysphoric Disorder (PMDD) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Premenstrual Dysphoric Disorder (PMDD) Market Size by Region (2019-2024)
8.4 Asia-Pacific Premenstrual Dysphoric Disorder (PMDD) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Premenstrual Dysphoric Disorder (PMDD) Market Size (2019-2030)
9.2 Latin America Premenstrual Dysphoric Disorder (PMDD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Premenstrual Dysphoric Disorder (PMDD) Market Size by Country (2019-2024)
9.4 Latin America Premenstrual Dysphoric Disorder (PMDD) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Premenstrual Dysphoric Disorder (PMDD) Market Size (2019-2030)
10.2 Middle East & Africa Premenstrual Dysphoric Disorder (PMDD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Premenstrual Dysphoric Disorder (PMDD) Market Size by Country (2019-2024)
10.4 Middle East & Africa Premenstrual Dysphoric Disorder (PMDD) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Detail
11.1.2 Teva Business Overview
11.1.3 Teva Premenstrual Dysphoric Disorder (PMDD) Introduction
11.1.4 Teva Revenue in Premenstrual Dysphoric Disorder (PMDD) Business (2019-2024)
11.1.5 Teva Recent Development
11.2 Eli Liliy
11.2.1 Eli Liliy Company Detail
11.2.2 Eli Liliy Business Overview
11.2.3 Eli Liliy Premenstrual Dysphoric Disorder (PMDD) Introduction
11.2.4 Eli Liliy Revenue in Premenstrual Dysphoric Disorder (PMDD) Business (2019-2024)
11.2.5 Eli Liliy Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Premenstrual Dysphoric Disorder (PMDD) Introduction
11.3.4 Pfizer Revenue in Premenstrual Dysphoric Disorder (PMDD) Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Premenstrual Dysphoric Disorder (PMDD) Introduction
11.4.4 Bayer Revenue in Premenstrual Dysphoric Disorder (PMDD) Business (2019-2024)
11.4.5 Bayer Recent Development
11.5 GSK
11.5.1 GSK Company Detail
11.5.2 GSK Business Overview
11.5.3 GSK Premenstrual Dysphoric Disorder (PMDD) Introduction
11.5.4 GSK Revenue in Premenstrual Dysphoric Disorder (PMDD) Business (2019-2024)
11.5.5 GSK Recent Development
11.6 Apotex
11.6.1 Apotex Company Detail
11.6.2 Apotex Business Overview
11.6.3 Apotex Premenstrual Dysphoric Disorder (PMDD) Introduction
11.6.4 Apotex Revenue in Premenstrual Dysphoric Disorder (PMDD) Business (2019-2024)
11.6.5 Apotex Recent Development
11.7 Bristol Laboratories
11.7.1 Bristol Laboratories Company Detail
11.7.2 Bristol Laboratories Business Overview
11.7.3 Bristol Laboratories Premenstrual Dysphoric Disorder (PMDD) Introduction
11.7.4 Bristol Laboratories Revenue in Premenstrual Dysphoric Disorder (PMDD) Business (2019-2024)
11.7.5 Bristol Laboratories Recent Development
11.8 Mylan
11.8.1 Mylan Company Detail
11.8.2 Mylan Business Overview
11.8.3 Mylan Premenstrual Dysphoric Disorder (PMDD) Introduction
11.8.4 Mylan Revenue in Premenstrual Dysphoric Disorder (PMDD) Business (2019-2024)
11.8.5 Mylan Recent Development
11.9 Allergan
11.9.1 Allergan Company Detail
11.9.2 Allergan Business Overview
11.9.3 Allergan Premenstrual Dysphoric Disorder (PMDD) Introduction
11.9.4 Allergan Revenue in Premenstrual Dysphoric Disorder (PMDD) Business (2019-2024)
11.9.5 Allergan Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
